AXT notifies Nasdaq of audit committee non-compliance following board member’s passing

AXT Inc. (AXTI) is currently non-compliant with Nasdaq listing rules due to its audit committee falling below the required three independent directors following a board member's death, with a cure period extending until July 2026. Concurrently, the company revised its Q2 revenue guidance downward to $17.5M-$18M, citing export control delays for gallium arsenide products and weaker demand in China, following a Q1 2025 earnings miss. Despite a reported 'WEAK' financial health score, AXT has recently secured necessary export permits for indium phosphide and announced a new equity incentive plan, while B. Riley maintained a Buy rating with a slightly lowered price target.

Analysis

AXT Inc. (AXTI) is facing significant operational and governance headwinds, reflected in a strongly negative ticker sentiment of -0.6. The company has revised its second-quarter revenue guidance downward to between $17.5 million and $18 million, a notable reduction from the prior forecast of $20 million to $22 million. This revision is directly attributed to delays in export permits for gallium arsenide and weakening demand in China, compounding the challenges from a Q1 2025 earnings miss where both revenue ($19.4 million) and EPS (-$0.19) fell short of analyst expectations. While the company reports a healthy current ratio of 1.99x, this is offset by an overall 'WEAK' financial health score from InvestingPro. Concurrently, AXT is non-compliant with Nasdaq listing rules due to its audit committee size falling below the required minimum following a board member's death. Although the company has a lengthy cure period until as late as July 2026 to resolve this, it adds a layer of governance risk. Positive counterpoints are limited but include securing necessary permits to resume indium phosphide exports and a maintained 'Buy' rating from B. Riley, albeit with a reduced price target of $4.30, suggesting some analysts see value beyond the current turmoil. The upcoming Q2 earnings release on July 31 will be a key event for assessing the true impact of these pressures.

Key Decisions for Investors

• Investors should closely monitor developments related to U.S. export controls and demand from China, as these are the primary drivers of the company's recent revenue guidance cut and operational uncertainty.
• The full Q2 financial results on July 31, 2025, represent a crucial catalyst, and a prudent approach may be to await this release for greater clarity on operational performance and management's outlook before committing capital.
• While a 'Buy' rating from B. Riley suggests potential value, this must be carefully weighed against significant risks, including the 'WEAK' financial health score, the recent earnings miss, and the unresolved Nasdaq governance issue.